David Lucchino

David L. Lucchino
Born	02.16.1969 (Age 48) Pittsburgh, PA, U.S.
Alma mater	Denison University Syracuse University Massachusetts Institute of Technology
Years active	1991 to present
Title	Co-founder, President and CEO, Frequency Therapeutics
Board member of	Massachusetts Biotechnology Council Multiple Myeloma Research Foundation
Spouse	Kimberley Kissam (m. 2007) divorced 2014 Carrie-Beth (Spina) Lucchino (m. 2016)
Parent(s)	Roberta F. Lucchino and Judge Frank J. Lucchino

David L. Lucchino is an American entrepreneur known for his work in the biotechnology and medical technology sectors.

Frequency Therapeutics’ CEO, president and co-founder, Lucchino also is the incoming chairman of the Massachusetts Biotechnology Council. Frequency is working on a treatment to reverse hearing loss.

Personal

A Pittsburgh native, Lucchino attended the all-male Central Catholic High School, graduating in 1987. He is the son of Judge Frank Lucchino and is the nephew of former Boston Red Sox president Larry Lucchino.

David L. Lucchino holds a Master of Business Administration degree from MIT Sloan School of Management as an Alfred P. Sloan Fellow. Lucchino also holds a Master of Science degree from Syracuse University and a Bachelor of Arts degree from Denison University.  He is a former member of the Board of Governors for the Sloan Fellows program.

Career

Lucchino began his career as a technology marketing executive. Lucchino co-founded and served as managing director of LaunchCyte, an investment firm that specializes in developing biomedical intellectual property. He led corporate development activities and secured funding for the firm’s portfolio companies. He is the  co-founder, CEO and president of Frequency Therapeutics. He co-founded Frequency Therapeutics in November 2014, first serving as chairman, and subsequently taking on the president and CEO roles alongside  biomedical engineer Jeffrey Karp and MIT professor, entrepreneur and inventor Robert Samuel Langer, Jr.  

Lucchino also oversaw the company's collaboration with GoogleX in the area of nanoparticle delivery, secured additional financing for Entrega, and served as Executive Entrepreneur in Residence at PureTech.

In 2006, while earning his MBA at MIT's Sloan School of Management, Lucchino was selected by Dr. Langer to team up with Dr. Christopher Loose to advance an implant surface technology that prevents blood clotting and infection. Lucchino’s team went on to win entrepreneurial competitions (by beating more than 300 teams collectively) at MIT, Harvard and Oxford universities. He continued with the team as it transformed into the company, Semprus BioSciences.

Under Lucchino’s stewardship as CEO, Semprus grew from two to 50 employees, and achieved FDA clearance and CE Mark approval for its flagship technology–Sustain™ Technology. He also secured $28.5 million in venture capital financing and $5.4 million in federal funding. The Semprus Sustain™ Technology was featured in Science Translational Medicine in 2012.

Lucchino served as Chief Executive Officer and President of Semprus BioSciences until its acquisition by Teleflex Medical, Inc. (NYSE: TFX) for $80 million. He continued to serve as a vice president of Semprus BioSciences overseeing the Sustain™ Technology for this 13,000-employee multi-national medical technology manufacturer.

Activities

He is an elected member of the Board of Directors of the Massachusetts Biotechnology Council, the leading not-for-profit organization that supports the region’s biotechnology industry, and is a Vice Chair of the board. He has been elected to a two-year term as Chair that will commence in 2018.

He is a Trustee of Mt. Auburn Hospital, a 200-bed Harvard Medical School facility, where he serves on the hospital's Audit/Compliance and Nomination committees.  

He also serves on the Audit Committee for CareGroup: the parent organization of Mt. Auburn, Beth Israel Deaconess Medical Center and The New England Baptist Hospital.

In 2013, Lucchino joined the board of the Multiple Myeloma Research Foundation.

He was a member of the Board of Directors of the Advanced Medical Technology Association (AdvaMed), the national trade association representing the U.S. medical device industry from 2010 to 2013, and served on AdvaMed's International Board Committee and Emerging Growth Company Council. Lucchino served the maximum term allowed by AdvaMed.  

A sought-after speaker and trusted business leader in Boston’s biotechnology and medical technology communities, Lucchino regularly appears on industry panels. He has been as a guest lecturer on entrepreneurship and innovation at colleges and universities including MIT (2007 through 2017); University of Pennsylvania Wharton School of Business (2010); Harvard Business School (2009 and 2010); Harvard Medical School (2010, 2011 and 2012); and the University of Pittsburgh (2012), where Lucchino delivered the Michael G. Wells Entrepreneurial Scholars Lecture as part of Translation Science 2012.

He was selected by the Boston Business Journal as one of Boston’s “40 under Forty” leading executives, has appeared as an industry commentator on WGBH-FM (NPR) “Innovation Hub,” and is a contributor to the WBUR-FM’s “Cognoscenti” online forum , and and the Boston Business Journal.

Outside the office, Lucchino is active with the National Outdoor Leadership School (NOLS). He was part of a NOLS expedition that climbed Alaska’s Denali, North America's tallest mountain, spent 95 days living in the Rocky Mountains as part of a leadership training program, and rafted down Idaho’s “River of No Return,” the Salmon River. Lucchino was honored by NOLS as the recipient of the 2013 NOLS Alumni Service Award, “given to a devoted [NOLS] alumnus who has served the school in exemplary ways as NOLS pursues its mission to teach leadership, conservation, and outdoor skills.” He has been on the NOLS advisory council since 2014.

Lucchino has participated four times as part of the Boston Red Sox’s “Team 9” in the annual Pan-Mass Challenge, the two-day, 190-mile cycling event that raises funds for adult and pediatric cancer care and research through The Jimmy Fund at Dana-Farber Cancer Institute in Boston.